

*Contains Nonbinding Recommendations*

*Draft – Not for Implementation*

**Draft Guidance on Maribavir**

**October 2024**

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA’s guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

---

**Active Ingredient:** Maribavir

**Dosage Form:** Tablet

**Route:** Oral

**Strength:** 200 mg

**Recommended Study:** One in vivo bioequivalence study with pharmacokinetic endpoints

1. Type of study: Fasting  
Design: Single-dose, two-treatment, two-period crossover in vivo  
Strength: 200 mg  
Subjects: Healthy males and non-pregnant, non-lactating females  
Additional comments: Exclude subjects with abnormal liver function tests and monitor liver function during the study.

**Analyte to measure:** Maribavir in plasma

**Bioequivalence based on (90% CI):** Maribavir

**Waiver request of in vivo testing:** Not applicable

**Dissolution test method and sampling times:** The dissolution information for this drug product can be found in the FDA’s Dissolution Methods database, <http://www.accessdata.fda.gov/scripts/cder/dissolution>. Conduct comparative dissolution testing on 12 dosage units for each of the test product and reference listed drug (RLD).<sup>1</sup> Specifications will be determined upon review of the abbreviated new drug application.

**Product-specific testing conditions for in vitro feeding tube studies:** The approved labeling for the reference listed drug product states that the product may be administered by a feeding tube i.e., nasogastric (NG) tube or orogastric (OG) tube. Conduct the in vitro feeding tube studies including comparative recovery testing with two repeated administrations, sedimentation volume and redispersibility testing, and in-use stability in designated dispersion media (i.e., water). For general procedures of in vitro feeding tube studies, refer to the most recent version of the FDA guidance for industry on *Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations*.<sup>a</sup>

Testing tubes: NG tube (10 French) and OG tube (10 French)

- Three different tube materials (e.g., PVC, silicone, polyurethane) and/or designs (e.g., various numbers of ports and/or eyes, retention balloons, open or closed distal end) for NG/OG tubes

Holding times of 0 and 15 minutes after dispersion

Testing strength: 200 mg (at a dose of 400 mg (2 tablets of 200 mg))

Dispersion and rinse media: Constitute oral suspension with 30 mL of drinking water or sterile water. For enteral administration (i.e., feeding tube), draw up suspension with an enteral syringe. Flush with 15 mL of water before and after enteral administration. Report the pH value of the water.<sup>a</sup>

---

**Document History:** Recommended May 2023; Revised October 2024

**Unique Agency Identifier:** PSG\_215596

---

<sup>a</sup> For the most recent version of a guidance, check the FDA guidance website at <https://www.fda.gov/regulatory-information/search-fda-guidance-documents>.

<sup>1</sup> If the RLD is not available, refer to the most recent version of the FDA guidance for industry on *Referencing Approved Drug Products in ANDA Submissions*.